Log in to search using one of your social media accounts:

 

Key Micronutrients and Food Groups in Late-Stage AMD Key Micronutrients and Food Groups in Late-Stage AMD
How does nutritional intake differ between healthy patients and those with late-stage age-related macular degeneration?The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2017 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

AMD: Brolucizumab Noninferior to Aflibercept in Early Study AMD: Brolucizumab Noninferior to Aflibercept in Early Study
A small phase 2 study suggests that brolucizumab is as safe and effective as aflibercept for treating patients with age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 18, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). (Source: Roche Media News)
Source: Roche Media News - September 8, 2017 Category: Pharmaceuticals Source Type: news

Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche today announced that the primary endpoint has not been met in Spectri, the first of two phase III studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). (Source: Roche Investor Update)
Source: Roche Investor Update - September 8, 2017 Category: Pharmaceuticals Source Type: news

Fund cheap supplement for degenerative eye disease, NHS urged
Antioxidant and zinc combo effective for slowing wet age-related macular degeneration Related items fromOnMedica Dementia risk no higher in people with AMD Age-Related Macular Degeneration First patient receives new treatment for AMD (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 25, 2017 Category: UK Health Source Type: news

Zink May Help Against Vision Loss in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says (Source: WebMD Health)
Source: WebMD Health - August 24, 2017 Category: Consumer Health News Source Type: news

Supplement May Help Against Vision-Robbing Disease in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says Source: HealthDay Related MedlinePlus Pages: Complementary and Integrative Medicine, Macular Degeneration (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 24, 2017 Category: Consumer Health News Source Type: news

Supplement May Help Against Vision-Robbing Disease in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says (Source: WebMD Health)
Source: WebMD Health - August 24, 2017 Category: Consumer Health News Source Type: news

Zinc May Help Against Vision Loss in Seniors
But no large studies prove the inexpensive pill slows age-related macular degeneration, eye expert says (Source: WebMD Health)
Source: WebMD Health - August 24, 2017 Category: Consumer Health News Source Type: news

New Anti-VEGF Drug Promising for Wet Macular Degeneration New Anti-VEGF Drug Promising for Wet Macular Degeneration
OPT-302, a new vascular endothelial growth factor (VEGF) inhibitor, appears to be safe and shows signs it could slow the progression of neovascular age-related macular degeneration.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 15, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Opthea touts data from wet-AMD trial
Opthea (ASX:OPT) touted additional data today from the Phase I/IIa trial of its wet age-related macular degeneration therapy, OPT-302. The 50-patient Phase I/IIa trial recruited participants who were either treatment-naive or previously treated with an intravitreal anti-VEGF therapy. Researchers evaluated OPT-302 as a monotherapy and in combination with Lucentis (ranibizumab). Get the full story at our sister site, Drug Delivery Business News. The post Opthea touts data from wet-AMD trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Opthea Source Type: news

Robot saved my sight by blasting my eye with radiotherapy
Michael Edwards (pictured), from Fawsley in Northamptonshire, was diagnosed with age-related macular degeneration - a leading cause of blindness in the over-60s. (Source: the Mail online | Health)
Source: the Mail online | Health - August 14, 2017 Category: Consumer Health News Source Type: news

Ophthotech eye-drug trial fails to meet primary endpoint
Shares in Ophthotech (NSDQ:OPHT) dipped to $2.46 apiece this morning after the company announced that its Phase III wet age-related macular degeneration trial failed to meet its primary endpoint. The New York-based company said that the addition of Fovista (pegpleranib) to Eylea or Avastin, both anti-VEGF therapies, did not significantly improve visual acuity after 12-months compared to Eylea or Avastin alone. Get the full story at our sister site, Drug Delivery Business News. The post Ophthotech eye-drug trial fails to meet primary endpoint appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat ophthotech Source Type: news

Antioxidants No Help for Age-Related Macular Degeneration (CME/CE)
(MedPage Today) -- Little or no benefit with wide range of supplements (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 11, 2017 Category: Geriatrics Source Type: news

Taking vitamin supplements will not prevent a common eye disease
Latest evidence published in the Cochrane Library suggests that taking vitamin supplements, such as vitamin E or beta-carotene, may not prevent the common eye disease age-related macular degeneration (AMD).  See additional resources at the bottom of this pageAge-related macular degeneration (AMD) is a progressive and sight-threatening disease affecting the central area of the retina and affects large numbers of people across the world. Population-based studies suggest that in older people (80 years and older), approximately one in three people have early signs of the disease.There are numerous unanswered questions in ...
Source: Cochrane News and Events - July 31, 2017 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Taking vitamin supplements may slow down the progression of a common eye disease
Latest evidence published in the Cochrane Library suggests that taking a multivitamin supplement that includes vitamin E, carotenoids (beta-carotene or lutein or zeaxanthin), vitamin C, and zinc may slow down the progression of the common eye disease age-related macular degeneration (AMD).See additional resources at the bottom of the pageAge-related macular degeneration (AMD) is a progressive and sight-threatening disease affecting the central area of the retina and affects large numbers of people across the world. Population-based studies suggest that in older people (80 years and older), approximately one in three people...
Source: Cochrane News and Events - July 31, 2017 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Using omega 3 fatty acids to treat Alzheimer's & other diseases?
(Louisiana State University Health Sciences Center) Understanding how dietary essential fatty acids work may lead to effective treatments for diseases and conditions such as stroke, Alzheimer's disease, age-related macular degeneration, Parkinson's disease and other retinal and neurodegenerative diseases. The key is to be able to intervene during the early stages of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2017 Category: International Medicine & Public Health Source Type: news

Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms Risk of Age-related Macular Degeneration Higher With Myeloproliferative Neoplasms
Patients with chronic myeloproliferative neoplasms (MPNs) have an increased risk of age-related macular degeneration (AMD), according to a Danish registry study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

An Eye to Health: Diet and Age-Related Macular Degeneration An Eye to Health: Diet and Age-Related Macular Degeneration
More and more studies are establishing a link between healthy eating and AMD development and progression.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2017 Category: Consumer Health News Tags: Ophthalmology Commentary Source Type: news

Dietary and lifestyle recommendations for patients at risk of macular degeneration
(Dove Medical Press) Age-related macular degeneration (AMD) is a major cause of severe visual impairment in older populations and is characterized by progressive destruction of the retinal pigment epithelial cells and photoreceptors due to low-grade inflammation, ischemia and oxidative stress. Studies show evidence that carotenoids and antioxidants derived either from the diet or from supplements may significantly reduce the risk of visual loss in these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 23, 2017 Category: International Medicine & Public Health Source Type: news

New hope for seniors with vision-robbing disease
The experimental drug for age-related macular degeneration aims to slow the destruction of light-sensing cells in the retina (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 22, 2017 Category: Consumer Health News Source Type: news

Drug shows promise against vision-robbing disease
An experimental drug is showing promise against an eye disease that blinds older adults, according to a US study. Age-related macular degeneration gradually erodes seniors' central vision. (Source: the Mail online | Health)
Source: the Mail online | Health - June 21, 2017 Category: Consumer Health News Source Type: news

Novartis trial results could spell trouble for Regeneron
Head-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN). Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies. Get the full story at our sister site, Drug Delivery Business News. The post Novartis trial results could spell trouble for Regeneron appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Inc. Novartis Regeneron Roche Source Type: news

Aflibercept May Be Effective for Resistant Exudative AMD Aflibercept May Be Effective for Resistant Exudative AMD
Aflibercept appears to improve outcomes in patients with exudative age-related macular degeneration (AMD) resistant to treatment with ranibizumab or bevacizumab, researchers from Norway report.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - June 14, 2017 Category: Opthalmology Tags: Ophthalmology News Source Type: news

How diet may affect age-related macular degeneration
Switching mice from a high glycemic diet to a low glycemic diet stopped the development of certain signs of age-related macular degeneration. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - June 6, 2017 Category: Consumer Health News Source Type: news

Implant for poor vision helps treat AMD
Age-related macular degeneration is a leading cause of blindness. Bronwen Dunn, 83, a retired administrator from Stoke-on-Trent, had a new operation to improve her sight. (Source: the Mail online | Health)
Source: the Mail online | Health - May 30, 2017 Category: Consumer Health News Source Type: news

Could eating THIS diet prevent blindness as you get older?
AGE-RELATED macular degeneration is the leading cause of blindness in those over 55 in developed countries, but eating low GI foods could stop it. (Source: Daily Express - Health)
Source: Daily Express - Health - May 19, 2017 Category: Consumer Health News Source Type: news

New gene therapy for vision loss is safe in humans, study suggests
In a small and preliminary clinical trial, researchers and their collaborators have shown that an experimental gene therapy that uses viruses to introduce a therapeutic gene into the eye is safe and that it may be effective in preserving the vision of people with wet age-related macular degeneration (AMD). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news

Eye drops for blindness could stop need for injections
Researchers from the University of Birmingham have developed eye drops that target age-related macular degeneration (AMD), the leading cause of sight loss in the UK and US. (Source: the Mail online | Health)
Source: the Mail online | Health - May 16, 2017 Category: Consumer Health News Source Type: news

Switching to a low-glycemic diet may stop age-related eye disease, study suggests
(Tufts University, Health Sciences Campus) Led by researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, a study in mice finds that development of age-related macular degeneration (AMD) could be arrested by switching from a high-glycemic to a low-glycemic diet. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 16, 2017 Category: International Medicine & Public Health Source Type: news

Revolutionary eye drops to treat age-related blindness
A type of eye drop has been developed that could potentially revolutionize the treatment of one of the leading causes of blindness, age-related macular degeneration. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 15, 2017 Category: Science Source Type: news

Many eye care providers may not catch macular degeneration
(Reuters Health) - Primary care optometrists and ophthalmologists may sometimes fail to detect age-related macular degeneration, the most common cause of vision impairment in the elderly, a recent U.S. study suggests. (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Dietary Supplements for Eye Conditions
Eye conditions that can lead to permanent visual impairment or blindness —including age-related macular degeneration (AMD), cataracts, diabetic retinopathy, and glaucoma—are serious public health problems. (Source: NCCAM Featured Content)
Source: NCCAM Featured Content - May 2, 2017 Category: Complementary Medicine Authors: NCCIH Source Type: news

Moving future regenerative therapies for blinding eye diseases to the clinic
A new report outlines steps to bringing future regenerative therapies for blinding diseases of the retina to patients. The retina is the light-sensitive tissue in the back of the eye. When stimulated, retinal neurons send visual information to the brain. Diseases like age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy can irreparably damage or destroy these neurons, which fail to regenerate on their  own.Language Undefined (Source: News from NEI)
Source: News from NEI - April 30, 2017 Category: Opthalmology Authors: haysdc Source Type: news

Study Finds Opticians Misdiagnose Eye Disease - AARP
9 hours ago ... Opticians misdiagnosed approximately 25% of patients who showed signs of Age -related Macular Degeneration, an eye disease that affects  ... (Source: AARP.org News)
Source: AARP.org News - April 29, 2017 Category: American Health Source Type: news

Underdiagnoses of age-related macular degeneration, findings suggest
Approximately 14 million Americans have age-related macular degeneration, and a new study suggests it may be underdiagnosed in primary eye care settings. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 27, 2017 Category: Science Source Type: news

Docs May Miss Major Cause of Vision Loss in Seniors
1 in 4 cases of age-related macular degeneration initially goes unrecognized, research suggests Source: HealthDay Related MedlinePlus Pages: Macular Degeneration, Seniors' Health, Vision Impairment and Blindness (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 27, 2017 Category: Consumer Health News Source Type: news

Docs May Miss Major Cause of Vision Loss in Seniors
THURSDAY, April 27, 2017 -- It's the leading cause of permanent vision loss for Americans, but a condition called age-related macular degeneration (AMD) may be going undiagnosed too often, new research suggests. The new study involved 644 people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 27, 2017 Category: Journals (General) Source Type: news

Age-Related Macular Degeneration in Patients With Uveitis Age-Related Macular Degeneration in Patients With Uveitis
What do we currently know about the prevalence of large drusen among patients with uveitis? Could they play a role in the pathogenesis of AMD?The British Journal of Ophthalmology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 25, 2017 Category: Allergy & Immunology Tags: Ophthalmology Journal Article Source Type: news

$2.4 million National Eye Institute grant to JAX for retinal pigment epithelium studies
(Jackson Laboratory) Funding will support study of diseases of the retinal pigment epithelium, with the goal of identifying druggable targets for age-related macular degeneration and other heritable retinal diseases. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 11, 2017 Category: Global & Universal Source Type: news

Effective communication from doctors could reduce anxiety for wet age-related macular degeneration patients
Highly effective current treatments for vision loss need to be allied with careful counseling to ensure patients maintain good psychological health as well as good vision, new research recommends. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 10, 2017 Category: Science Source Type: news

Home-based Macular Degeneration Monitoring Appears Cost Effective Home-based Macular Degeneration Monitoring Appears Cost Effective
Home telemonitoring of people at risk for age-related macular degeneration (AMD) is potentially cost-effective, according to an economic analysis using a simulation model.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 5, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Physician Who Tricked Patients Into Surgery Gets 10 Years Physician Who Tricked Patients Into Surgery Gets 10 Years
David Ming Pon, MD, bilked Medicare by telling patients they needed laser treatment for wet age-related macular degeneration they didn't have. Make him an example, two peers said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 21, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Opthea gets positive feedback from European regulatory groups for wet-AMD injection
Opthea (ASX:OPT) said today that it received positive feedback from meetings with the U.K.’s Medicines and Healthcare Products Regulatory Agency and Sweden’s Medical Products Agency over its OPT-302 therapy for the treatment of wet age-related macular degeneration. The Australia-based company’s OPT-302 therapy consists of a soluble form of vascular endothelial growth factor receptor 3 that blocks the activity of 2 proteins that cause blood vessels to grow and leak. It is being evaluated in a phase 1/2 clinical trial in patients with wet AMD as a monotherapy and with ranibizumab, delivered as monthly intra...
Source: Mass Device - March 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Regulatory/Clearance Wall Street Beat Opthea Source Type: news

Behavioral Activation Plus Low Vision Rehab Beneficial in AMD
More effective than conventional optometric low vision services for age - related macular degeneration (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - March 20, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Ophthalmology, Psychiatry, Journal, Source Type: news

Study: Vision loss treatment linked to higher risk of glaucoma surgery
Photo credit: Laitr Keiows Researchers from the University of British Columbia found that patients with age-related macular degeneration who had at least 7 eye injections per year had a heightened risk of having glaucoma surgery. The team’s findings were published this week in JAMA Ophthalmology. Patients with wet age-related macular degeneration and diabeteic macular edema, common causes of vision loss, are often treated with intravitreous injections of anti-vascular endothelial growth factor. Previous work has established that these treatments improve visual outcomes for many patients. Get the full story ...
Source: Mass Device - March 17, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Optical/Ophthalmic Research & Development Surgical University of British Columbia Source Type: news

[In Depth] iPS cell therapy reported safe
Japanese researchers reported this week that the first trial of induced pluripotent stem (iPS) cells in a human has proved safe and effective in halting the progression of age-related macular degeneration (AMD), though there was minimal improvement in vision. AMD is the leading cause of vision loss in the elderly. The team took a skin sample from the patient and derived iPS cells, which can be used to create all the tissues within a body. They differentiated the iPS cells into the kind of retinal tissue damaged by AMD and surgically slipped a small replacement graft into one of the patient's eyes. Starting with the patient...
Source: ScienceNOW - March 16, 2017 Category: Science Authors: Dennis Normile Tags: Regenerative Medicine Source Type: news

Repeated eye injections for age-related macular degeneration associated with increased risk for glaucoma
Patients with age-related macular degeneration who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 16, 2017 Category: Science Source Type: news

For Seniors, Treatment for One Eye Disease May Cause Another
THURSDAY, March 16, 2017 -- Drugs that preserve vision in people with the eye disease called age-related macular degeneration might increase the risk of another eye condition -- glaucoma, a new study suggests. People who received at least seven eye... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 16, 2017 Category: Journals (General) Source Type: news

Experimental stem cell treatment stabilizes macular degeneration
As we grow older, macular degeneration threatens our eyesight. An experimental stem cell treatment for age-related macular degeneration proved effective at halting retinal decline while causing no serious side effects up to one year later, a new study published in the New England Journal of Medicine found. This is the first treatment using personalized, genetically identical cells derived from the patient. (Source: CNN.com - Health)
Source: CNN.com - Health - March 15, 2017 Category: Consumer Health News Source Type: news